STORM Therapeutics to present at Bio€quity Europe 2018
10 May 2018, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it will be giving a company presentation at Bio€quity Europe 2018, Ghent, Belgium, 14 - 16 May 2018.
Keith Blundy, CEO of STORM Therapeutics will be presenting on Wednesday, 16 May 2016 at 9:10am CEST in Rector Gillis Suit, Level 1, Het Pand, Onderbergen 1, Ghent, Belgium.
Now celebrating its 19th meeting, Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals.
For further information:
STORM Therapeutics Ltd
T: +44 (0)1223 804174
Optimum Strategic Communications
Mary Clark, Hollie Vile
Tel: +44 203 714 1787
NOTES TO EDITORS
STORM Therapeutics, founded in 2015, is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.
STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, IP Group and Taiho Ventures LLC, who share the founders’ ambitions to build a world-leading company in the field. To date, STORM Therapeutics has raised £16million of funding.